Post IPO investors in Boston, Massachusetts
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Investor | Type | Location | Phone | |
|---|---|---|---|---|
| RA Capital Management | Startup incubator | Boston, United States | •••@racap.com | 617.77••• |
| SV Health Investors | Private equity firm | Boston, United States | •••@svlsa.com | +1 617••• |
| HarbourVest Partners | Private equity firm | Boston, United States | •••@harbourvest.com | +1 617••• |
| Advent International | Private equity firm | Boston, United States | •••@adventinternational.com | 212 81••• |
| Bain Capital | Private equity firm | Boston, United States | •••@baincapital.com | +1 617••• |
| Omega Funds | Secondary purchaser | Boston, United States | •••@omegafunds.net | |
| Adage Capital Management | Government investment office | Boston, United States | •••@adagecapital.com | 617-86••• |
| Third Rock Ventures | Venture capital firm | Boston, United States | •••@thirdrockventures.com | (415) ••• |
8 rows of the CSV in 5 of its 15 columns, email and phone masked.
| Firm | Person | Title | Verified email | |
|---|---|---|---|---|
| RA Capital Management | P••• K••• | Managing Partner | p•••@racap.com | In the CSV |
| SV Health Investors | K••• B••• | Managing Partner | k•••@svhealthinvestors.com | In the CSV |
| TA Associates | R••• B••• | Managing Director, Co-Head Financial Services, Americas | r•••@ta.com | In the CSV |
| HarbourVest Partners | B••• K••• | Managing Director | b•••@harbourvest.com | In the CSV |
| Advent International | T••• G••• | Managing Partner | t•••@adventinternational.com | In the CSV |
5 verified partner contact rows from organizations on this list, names and emails masked.
- 20 of the 33 post ipo investors in Boston, Massachusetts have a published email address, 21 a phone number and 31 a website.
- Fidelity has the most recorded investments, 586, 178 of them as lead investor.
- 10 of them are investors in at least one company that closed its most recent round in the last 12 months.
- RA Capital Management is an investor in 9 of those companies, more than any other investor on this list.
- The newest round among their portfolio companies is Delix Therapeutics' $100.0M Series C on 9 November 2026.
- Software is the most common sector across their 240 portfolio companies (57%).
- Early stage venture is the most common investment stage, recorded for 31 of them (94%).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Post IPO investors in Boston, Massachusetts
30 of 33, most investments first| # | Investor | Type | Location | Invests in | Latest portfolio companies | Funded, 12 months | Investments | Lead | Exits | Phone | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity | Investment bank | Boston, United States | Health care, Hardware | Zipline International, Tenstorrent, SiMa.ai | 7 | 586 | 178 | 285 | +1-866••• | In the CSV | |
| 2 | RA Capital Management | Startup incubator, Private equity firm | Boston, United States | Health care, Biotech | Delix Therapeutics, Superluminal Medicines, Claris Biotherapeutics | 9 | 544 | 183 | 243 | •••@racap.com | 617.77••• | In the CSV |
| 3 | SV Health Investors | Private equity firm, Venture capital firm | Boston, United States | Health care, Biotech | Alchemab Therapeutics | 1 | 325 | 76 | 95 | •••@svlsa.com | +1 617••• | In the CSV |
| 4 | TA Associates | Private equity firm | Boston, United States | Hardware, Artificial intelligence | Wunder Mobility, Stackline, Thinkproject | 317 | 173 | 194 | +1.617••• | In the CSV | ||
| 5 | Cormorant Asset Management | Hedge fund | Boston, United States | Health care, Biotech | Triveni Bio, Third Arc Bio, BlossomHill Therapeutics | 4 | 276 | 58 | 141 | In the CSV | ||
| 6 | HarbourVest Partners | Private equity firm | Boston, United States | Fintech, Hardware | Varo Bank | 1 | 273 | 52 | 147 | •••@harbourvest.com | +1 617••• | In the CSV |
| 7 | Advent International | Private equity firm | Boston, United States | Fintech, Hardware | Coralogix, KreditBee | 2 | 234 | 97 | 89 | •••@adventinternational.com | 212 81••• | In the CSV |
| 8 | Bain Capital | Private equity firm, Venture capital firm | Boston, United States | Fintech, Hardware | Mintlify | 1 | 198 | 89 | 89 | •••@baincapital.com | +1 617••• | In the CSV |
| 9 | Omega Funds | Secondary purchaser, Venture capital firm | Boston, United States | Biotech, Health care | FoRx Therapeutics | 1 | 161 | 37 | 75 | •••@omegafunds.net | In the CSV | |
| 10 | Adage Capital Management | Government investment office | Boston, United States | Artificial intelligence, Health care | Welldoc | 161 | 13 | 119 | •••@adagecapital.com | 617-86••• | In the CSV | |
| 11 | Third Rock Ventures | Venture capital firm | Boston, United States | Biotech, Health care | Terremoto Biosciences | 1 | 154 | 69 | 44 | •••@thirdrockventures.com | (415) ••• | In the CSV |
| 12 | HLM Venture Partners | Venture capital firm | Boston, United States | Health care, Hardware | ArroHealth, PatientPop, ClearDATA | 138 | 41 | 51 | •••@hlmvp.com | 617-26••• | In the CSV | |
| 13 | Trustbridge Partners | Private equity firm | Boston, United States | Education, Commerce | Hope Medicine, Zilliz, huoban.com | 122 | 44 | 21 | •••@trustbridgepartners.com | In the CSV | ||
| 14 | RockPort Capital | Venture capital firm | Boston, United States | Hardware, Biotech | NewLeaf Symbiotics, EcoFactor, Gazelle | 108 | 25 | 26 | 415-78••• | In the CSV | ||
| 15 | Atreides Management | Hedge fund, Venture capital firm | Boston, United States | Hardware, Cybersecurity | DustPhotonics, Chain Reaction | 89 | 15 | 9 | •••@atreidesmgmt.com | 617-42••• | In the CSV | |
| 16 | Eventide | Private equity firm, Venture capital firm | Boston, United States | 64 | 14 | 36 | •••@eventidefunds.com | +1-877••• | In the CSV | |||
| 17 | JDRF T1D Fund | Venture capital firm | Boston, United States | Biotech, Health care | i2o Therapeutics | 54 | 13 | 14 | •••@jdrf.org | 212-68••• | In the CSV | |
| 18 | K2 HealthVentures | Private equity firm, Venture capital firm | Boston, United States | Biotech, Health care | Click Therapeutics | 1 | 51 | 28 | 24 | •••@k2hv.com | In the CSV | |
| 19 | Material Impact | Venture capital firm | Boston, United States | Biotech, Hardware | Actnano, Tierra Biosciences, Talus Renewables | 45 | 22 | 3 | In the CSV | |||
| 20 | PAR Capital Management | Venture capital firm | Boston, United States | Software | Journera, Routehappy | 39 | 9 | 11 | •••@parcapital.com | (617) ••• | In the CSV | |
| 21 | The Baupost Group | Hedge fund | Boston, United States | Commerce | Just Eat Takeaway.com | 38 | 13 | 20 | •••@baupost.com | 617-21••• | In the CSV | |
| 22 | Monashee Investment Management | Hedge fund | Boston, United States | 30 | 1 | 18 | •••@monasheecap.com | In the CSV | ||||
| 23 | Wavecrest Growth Partners | Private equity firm | Boston, United States | Commerce, Artificial intelligence | HICX, Dark Pools, MikMak | 28 | 21 | 6 | •••@wavecrestgrowth.com | (857) ••• | In the CSV | |
| 24 | Columbia Threadneedle Investments | Corporate venture arm | Boston, United States | 24 | 4 | 19 | +1 800••• | In the CSV | ||||
| 25 | Spring Lane Capital | Private equity firm | Boston, United States | 16 | 16 | 3 | •••@springlanecapital.com | (514)7••• | In the CSV | |||
| 26 | AMR Action Fund | Venture capital firm | Boston, United States | Biotech, Health care | Elion Therapeutics | 15 | 12 | 4 | In the CSV | |||
| 27 | SVB Securities | Investment bank | Boston, United States | 4 | 1 | 2 | +1 617••• | In the CSV | ||||
| 28 | Aghadiuno John | Angel investor | Boston, United States | Commerce | MassMarketplace, Woofpage | 4 | 0 | 0 | In the CSV | |||
| 29 | ShawSpring Partners | Hedge fund, Private equity firm | Boston, United States | 2 | 1 | 0 | •••@shawspring.com | In the CSV | ||||
| 30 | Acquis Capital | Family office, Venture capital firm | Boston, United States | 0 | 0 | 0 | (617)3••• | In the CSV |
Table 1. Post IPO investors in Boston, Massachusetts: the first 30 by recorded investments with a website and a location. Email and phone are masked here and complete in the CSV. Source: FundingWatcher. Data as of 16 November 2026. Base: 33.
Most active in the last 12 months
By portfolio companies funded| # | Investor | Location | Funded, 12 months | Portfolio | Latest |
|---|---|---|---|---|---|
| 1 | RA Capital Management | Boston, United States | 9 | 47 | Delix Therapeutics, Superluminal Medicines, Claris Biotherapeutics |
| 2 | Fidelity | Boston, United States | 7 | 40 | Zipline International, Tenstorrent, SiMa.ai |
| 3 | Cormorant Asset Management | Boston, United States | 4 | 13 | Triveni Bio, Third Arc Bio, BlossomHill Therapeutics |
| 4 | Advent International | Boston, United States | 2 | 17 | Coralogix, KreditBee |
| 5 | SV Health Investors | Boston, United States | 1 | 9 | Alchemab Therapeutics |
| 6 | Third Rock Ventures | Boston, United States | 1 | 5 | Terremoto Biosciences |
| 7 | Bain Capital | Boston, United States | 1 | 27 | Mintlify |
| 8 | K2 HealthVentures | Boston, United States | 1 | 1 | Click Therapeutics |
| 9 | HarbourVest Partners | Boston, United States | 1 | 19 | Varo Bank |
| 10 | Omega Funds | Boston, United States | 1 | 11 | FoRx Therapeutics |
Table 2. Post IPO investors in Boston, Massachusetts: investors in the most companies whose most recent round falls in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Latest rounds in their portfolios
Newest first| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors on this list | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Boston, United States | Series C | $100.0M | 2026-11-09 | $244.1M | RA Capital Management | 11 to 50 | 2019 |
| Zipline International Unicorn | Zipline designs, manufactures, and operates drones that deliver medical products. | Hardware | South San Francisco, United States | Series I | $1.5B | 2026-11-05 | $3.6B | Fidelity | 1,001 to 5,000 | 2011 |
| Tenstorrent Unicorn | Tenstorrent develops AI processors and software for machine learning and data-intensive workloads. | Artificial intelligence | Santa Clara, United States | Series E | $1.5B | 2026-10-19 | $2.5B | Fidelity | 501 to 1,000 | 2016 |
| SiMa.ai | SiMa.ai develops hardware and software for deploying physical AI applications at the edge. | Artificial intelligence | San Jose, United States | Series C | $150.0M | 2026-09-28 | $505.0M | Fidelity | 101 to 250 | 2018 |
| Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Boston, United States | Series B | $65.5M | 2026-09-03 | $223.5M | RA Capital Management | 11 to 50 | 2022 |
| Claris Biotherapeutics | Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. | Biotech | Jersey City, United States | Series B | $118.0M | 2026-07-28 | $225.1M | RA Capital Management | 1 to 10 | 2018 |
| Alchemab Therapeutics | Alchemab Therapeutics develops protective antibodies to prevent hard-to-treat diseases. | Biotech | London, United Kingdom | Series A | $33.6M | 2026-07-09 | $151.1M | RA Capital Management, SV Health Investors | 51 to 100 | 2019 |
| Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown, United States | Series C | $65.0M | 2026-06-17 | $272.0M | Cormorant Asset Management | 11 to 50 | 2019 |
| Element Biosciences Unicorn | Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. | Biotech | San Diego, United States | Series E | $277.0M | 2026-06-09 | $678.0M | Fidelity, RA Capital Management | 251 to 500 | 2017 |
| Coralogix | Coralogix provides a SaaS platform that uses machine learning to support software delivery and maintenance. | Artificial intelligence | Boston, United States | Series F | $200.0M | 2026-06-03 | $550.8M | Advent International | 501 to 1,000 | 2014 |
Table 3. Post IPO investors in Boston, Massachusetts: the 10 most recent rounds of companies they back. Source: FundingWatcher. Data as of 16 November 2026.
Portfolio sectors
| Portfolio sectors | Companies | Share |
|---|---|---|
| Software | 137 | 57% |
| Health care | 99 | 41% |
| Biotech | 82 | 34% |
| Hardware | 45 | 19% |
| Artificial intelligence | 40 | 17% |
| Fintech | 25 | 10% |
| Commerce | 23 | 10% |
| Education | 11 | 5% |
| Cybersecurity | 11 | 5% |
| Energy | 5 | 2% |
Table 4. Post IPO investors in Boston, Massachusetts: portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Investment stages
| Investment stages | Investors | Share |
|---|---|---|
| Post IPO investors | 33 | 100% |
| Early stage investors | 31 | 94% |
| Late stage investors | 27 | 82% |
| Private equity investors | 21 | 64% |
| Seed investors | 15 | 45% |
| Venture investors | 15 | 45% |
| Debt investors | 11 | 33% |
| Convertible note investors | 5 | 15% |
Table 5. Post IPO investors in Boston, Massachusetts by stage they invest at. Source: FundingWatcher. Data as of 16 November 2026.
Founded
| Founded | Investors | Share |
|---|---|---|
| 2020s | 1 | 3% |
| 2010s | 10 | 34% |
| 2000s | 6 | 21% |
| 1990s | 4 | 14% |
| 1980s | 6 | 21% |
| 1960s | 1 | 3% |
Table 6. Post IPO investors in Boston, Massachusetts by founding decade. Source: FundingWatcher. Data as of 16 November 2026.
Method
- An investor is on this list when its recorded investment stages include post ipo investors and its headquarters is in Boston, Massachusetts. On 16 November 2026 that is 33 investors.
- 20 rows carry an email address and 21 a phone number from the investor file. Investments, lead investments and exits are the counts the source records.
- The table prints the first 30 rows by recorded investments that carry a website and a location, with email and phone masked. The CSV carries all 33 rows: 2 have no website and 0 no location.
Sources, fields and exclusions of both files: Method.
Questions
- How many post ipo investors in Boston, Massachusetts are on the list?
- 33, in the file dated 16 November 2026. 10 of them invested in a company whose most recent round falls in the last 12 months.
- How many have an email address?
- 20 of the 33 carry an email address in the download and 21 a phone number.
- What does the CSV contain?
- One row per investor, 15 columns: name, types, stages, city, region, country, founded, website, linkedin, investments, funded_last_12m, exits, lead_investments, email, phone.
- How much does the list cost?
- $29 one-time for all 33 rows, no account. Every investor and every startup, two files, cost $99. With partner contacts, up to 2 per firm compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV with 33 rows, 20 firm email addresses and 21 phone numbers, on the page after payment and by mail. The emails are the address a firm publishes: 14 of the 20 are inboxes such as info@ or contact@. No partner names.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.